XML 46 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statement of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Cash Flows from Operating Activities of Continuing Operations      
Net income from continuing operations $ 377 $ 14,526 $ 12,358
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:      
Amortization 2,044 2,085 1,636
Depreciation 1,828 1,824 1,578
Intangible asset impairment charges 792 1,749 302
(Income) loss from investments in equity securities, net (340) 1,419 (1,940)
Charge for the acquisition of Prometheus Biosciences, Inc. 10,217 0 0
Charge for the acquisition of Imago BioSciences, Inc. 1,192 0 0
Charge for the acquisition of Pandion Therapeutics, Inc. 0 0 1,556
Deferred income taxes (1,899) (1,568) 187
Share-based compensation 645 541 479
Other 355 1,301 805
Net changes in assets and liabilities:      
Accounts receivable (1,148) (644) (2,033)
Inventories (816) (161) (674)
Trade accounts payable (380) (289) 405
Accrued and other current liabilities 1,783 (50) 277
Income taxes payable 214 380 (540)
Noncurrent liabilities 456 (545) 484
Other (2,314) (1,473) (1,758)
Net Cash Provided by Operating Activities of Continuing Operations 13,006 19,095 13,122
Cash Flows from Investing Activities of Continuing Operations      
Capital expenditures (3,863) (4,388) (4,448)
Purchases of securities and other investments (955) (1,204) (1)
Proceeds from sale of Seagen Inc. common stock 1,145 0 0
Proceeds from sales of securities and other investments 1,658 721 1,026
Acquisition of Prometheus Biosciences, Inc., net of cash acquired (10,705) 0 0
Acquisition of Imago BioSciences Inc., net of cash acquired (1,327) 0 0
Acquisition of Acceleron Pharma Inc., net of cash acquired 0 0 (11,174)
Acquisition of Pandion Therapeutics, Inc., net of cash acquired 0 0 (1,554)
Other acquisitions, net of cash acquired 0 (121) (179)
Other (36) 32 (91)
Net Cash Used in Investing Activities of Continuing Operations (14,083) (4,960) (16,421)
Cash Flows from Financing Activities of Continuing Operations      
Net change in short-term borrowings 0 0 (3,986)
Payments on debt (1,755) (2,251) (2,319)
Proceeds from issuance of debt 5,939 0 7,936
Distribution from Organon & Co. 0 0 9,000
Purchases of treasury stock (1,346) 0 (840)
Dividends paid to stockholders (7,445) (7,012) (6,610)
Proceeds from exercise of stock options 125 384 202
Other (328) (240) (286)
Net Cash (Used in) Provided by Financing Activities of Continuing Operations (4,810) (9,119) 3,097
Cash Flows from Discontinued Operations      
Net cash provided by operating activities 0 0 987
Net cash used in investing activities 0 0 (134)
Net cash used in financing activities 0 0 (504)
Net Cash Flows Provided by Discontinued Operations 0 0 349
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash 23 (410) (133)
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash (5,864) 4,606 14
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $79, $71 and $103 of restricted cash at January 1, 2023, 2022 and 2021, respectively, included in Other current assets) 12,773 8,167 8,153
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $68, $79 and $71 of restricted cash at December 31, 2023, 2022 and 2021, respectively, included in Other current assets) $ 6,909 $ 12,773 $ 8,167